Skip to main content

Table 3 Results of Cox model of recurrent events of hospitalization in HF patients

From: Impact of multi-disciplinary treatment strategy on systolic heart failure outcome

Variables β S.E. HR HR 95% CI p
Group
 non-HFDMP ref.   1.00   
 HFDMP −1.03 0.62 0.36 0.11 – 1.19 .09
Age 0.03 0.02 1.03 0.99 – 1.06 .14
Gender
 Female ref.   1.00   
 Male 0.23 0.29 1.26 0.71 – 2.22 .43
Ischemic CM −0.32 0.46 0.72 0.29 – 1.78 .48
Hypertension −0.42 0.48 0.65 0.25 – 1.68 .38
Diabetes mellitus −0.55 0.38 0.58 0.28 – 1.21 .14
Hyperlipidemia 0.00 0.68 1.00 0.27 – 3.77 1.00
Stroke 0.78 0.56 2.18 0.72 – 6.54 .17
Old MI 0.10 0.59 1.11 0.35 – 3.51 .87
PAD 0.51 0.52 1.67 0.60 – 4.67 .33
CKD −0.78 0.52 0.46 0.17 – 1.26 .13
Atrial Fibrillation
 Without AF ref.   1.00   
 Paroxysmal −0.30 0.61 0.74 0.22 – 2.47 .63
 Persistent −2.06 1.05 0.13 0.02 – 1.01 .05
 Permanent −0.32 0.79 0.73 0.15 – 3.42 .69
PCI 0.44 0.64 1.55 0.44 – 5.39 .49
LVEF 0.01 0.03 1.01 0.96 – 1.06 .73
Medication
 ACEI/ARB 0.13 0.58 1.14 0.37 – 3.54 .82
 β-blocker −1.70 0.44 0.18 0.08 – 0.43 <.01
 Aldactone 0.98 0.54 2.68 0.93 – 7.68 .07
 Diuretics −0.79 0.54 0.45 0.16 – 1.29 .14
 Digoxin 0.22 0.47 1.25 0.50 – 3.10 .64
 ICD 0.96 0.61 2.60 0.78 – 8.63 .12
 CRT −1.15 1.37 0.32 0.02 – 4.65  
  1. Abbreviations: HFDMP heart failure disease management program, CM cardiomyopathy, HF heart failure, MI myocardial infarction, PAD peripheral artery disease, CKD chronic kidney disease, AF atrial fibrillation, PCI percutaneous coronary intervention, LVEF left ventricular ejection fraction, ACEI angiotensin converted enzyme inhibitor, ARB angiotensin receptor blocker, ICD implantable cardioverter defibrillator, CRT cardiac resynchronization therapy, HR Hazard ratio, CI confidence interval